Thus, co‐targeting Ephs, TRKs and the c‐Kit pathway may be effective in eliminating the PI3K‐independent CSC population, providing potential targets for future development of a novel anti‐CSC therapeutic approach for HNSCC patients, particularly in patients with PIK3CA amplification. This evidence concerns the gene KIT and head and neck squamous cell carcinoma.